Business Standard

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

SI Team  |  Mumbai 

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

RECOMMENDED FOR YOU

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

image

LIVE MARKET

BSE

  ( %)

NSE

  ( %)

Widgets Magazine

More News

STOCK WATCH

Company Price() Chg(%)
Indbull.RealEst. 63.45 11.61
D B Realty 50.05 7.40
Bliss GVS Pharma 117.00 7.04
Castex Tech 6.85 4.90
Westlife Develop 205.10 4.75
> More on BSE Gainers
Company Price() Chg(%)
Indbull.RealEst. 63.50 11.70
D B Realty 50.10 7.17
Bliss GVS Pharma 117.25 6.59
Castex Tech 6.75 4.65
CEAT 1173.60 4.64
> More on NSE Gainers
Company Price() Chg(%)
Jubilant Food. 1195.40 -10.25
Kwality 118.40 -6.48
I D F C 43.50 -6.35
Tata Elxsi 1913.05 -6.14
Gateway Distr. 283.65 -5.37
> More on BSE Gainers
Company Price() Chg(%)
Jubilant Food. 1190.65 -10.64
I D F C 43.40 -6.57
Tata Elxsi 1911.10 -6.38
Kwality 118.70 -6.35
Gateway Distr. 281.60 -6.07
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard